1
|
Shafiee F, Sarbaz M, Marouzi P, Banaye Yazdipour A, Kimiafar K. Providing a framework for evaluation disease registry and health outcomes Software: Updating the CIPROS checklist. J Biomed Inform 2024; 149:104574. [PMID: 38101688 DOI: 10.1016/j.jbi.2023.104574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2023] [Revised: 11/27/2023] [Accepted: 12/08/2023] [Indexed: 12/17/2023]
Abstract
BACKGROUND AND AIMS Properly designed and implemented registry systems play an important role in improving health outcomes and reducing care costs, and can provide a true representation of clinical practice, disease outcomes, safety, and efficacy. Therefore, the aim of this study was to redesign and develop a checklist with items for a patient registry software system (CIPROS) Checklist. METHOD The study is descriptive-cross-sectional. The extraction of the data elements of the checklist was first done through a comprehensive review of the texts in PubMed, Science Direct and Scopus databases and receiving articles related to the evaluation of registry systems. Based on the extracted data, a five-point Likert scale questionnaire was created and 30 experts in this field were asked for their opinions using the two-step Delphi method. RESULTS A total of 100 information items were determined as a registry software evaluation checklist. This checklist included 12 groups of software architecture factors, development, interfaces and interactivity, semantics and standardization, internationality, data management, data quality and usability, data analysis, security, privacy, organizational, education and public factors. CONCLUSION By using the results of this research, it is possible to identify the defects and possible strengths of the registry software and put it at the disposal of the relevant officials to make a decision in this field. In this way, among the designers and developers of these softwares, the best and most appropriate ones are selected with the needs of the registry programs.
Collapse
Affiliation(s)
- Fatemeh Shafiee
- Department of Health Information Technology, School of Paramedical and Rehabilitation Sciences, Mashhad University of Medical Sciences, Mashhad, Iran.
| | - Masoume Sarbaz
- Department of Health Information Technology, School of Paramedical and Rehabilitation Sciences, Mashhad University of Medical Sciences, Mashhad, Iran.
| | - Parviz Marouzi
- Department of Health Information Technology, School of Paramedical and Rehabilitation Sciences, Mashhad University of Medical Sciences, Mashhad, Iran.
| | - Alireza Banaye Yazdipour
- Department of Health Information Technology, School of Paramedical and Rehabilitation Sciences, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Health Information Management and Medical Informatics, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran; Students' Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran.
| | - Khalil Kimiafar
- Department of Health Information Technology, School of Paramedical and Rehabilitation Sciences, Mashhad University of Medical Sciences, Mashhad, Iran.
| |
Collapse
|
2
|
Nguyen LB, Vu LG, Le TT, Nguyen XT, Dao NG, Nguyen DC, Huyen Thi Dang T, Vu TMT, Boyer L, Fond G, Auquier P, Latkin CA, Zhang MWB, Ho RCM, Ho CSH. Impact of interventions on the quality of life of cancer patients: a systematic review and meta-analysis of longitudinal research. Health Qual Life Outcomes 2023; 21:112. [PMID: 37821985 PMCID: PMC10566122 DOI: 10.1186/s12955-023-02189-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Accepted: 09/11/2023] [Indexed: 10/13/2023] Open
Abstract
The impact of cancer interventions has been conducted in several research due to the significant burden of this non-communicable disease. The interventions that played an important role in the improvement of the patient's quality of life (QoL) and health-related quality of life (HRQL) can be classified into two main groups: pharmaceutical and non-pharmacological methods. However, studies so far often analyze a specific group of interventions for specific types of cancer. Thus, in this systematic review and meta-analysis, we synthesized the overall impact of cancer interventions on patients' quality of life in several cancers.In this research, we followed the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) to search the longitudinal original research on the Web of Science (WOS) database. After that, the Newcastle-Ottawa Scale (NOS) and Jadad Scale were used to assess the quality of non-randomized control trials and randomized control trials, respectively. Then, the characteristics of the included studies were described in the six main fields table and the random effect model with robust estimation was applied to analyze the impact of interventions on the health utility of patients.From the database, 122 longitudinal original research were included in the meta-regression, with most of them having high or fair quality. The European Organization for the research and treatment of cancer scale for quality of life (EORTC-QLQ) was the most used health utility measurement at 65.15%. In the adjusted effect models, the Visual Analogue Scale (VAS) had significant statistics in all models when we compared it with the EQ-5D Scale (p < 0.05) and several types of cancer such as breast, lung, and prostate cancer had significant statistics when comparing with hematological cancer in the model types of cancer (p < 0.01). Moreover, radiotherapy, screening, and a combination of chemotherapy and best supportive care also had significant statistics (p < 0.01) in the model of interventions when compared with radiotherapy applied only. Our research can suggest a vital combination of both pharmaceutical and non-pharmacological interventions to improve the quality of life of some common types of cancer patients.
Collapse
Affiliation(s)
- Long Bao Nguyen
- Institute for Preventive Medicine and Public Health, Hanoi Medical University, Hanoi, 100000, Vietnam
| | - Linh Gia Vu
- Institute for Global Health Innovations, Duy Tan University, 550000, Da Nang, Vietnam
- Faculty of Medicine, Duy Tan University, Da Nang, 550000, Vietnam
| | - Thanh Thien Le
- Department of Biomedical Engineering, Tufts University, 200 College Avenue, Medford, MA, 02155, USA
| | | | - Nam Gia Dao
- Institute for Global Health Innovations, Duy Tan University, 550000, Da Nang, Vietnam
- Faculty of Medicine, Duy Tan University, Da Nang, 550000, Vietnam
| | - Duy Cao Nguyen
- Institute for Global Health Innovations, Duy Tan University, 550000, Da Nang, Vietnam.
- Faculty of Medicine, Duy Tan University, Da Nang, 550000, Vietnam.
| | | | - Thuc Minh Thi Vu
- Institute of Health Economics and Technology (iHEAT), Hanoi, Vietnam
| | - Laurent Boyer
- Research Centre on Health Services and Quality of Life, Aix Marseille University, 27, boulevard Jean-Moulin, CEReSS, Marseille cedex 05, 3279, 13385, France
| | - Guillaume Fond
- Research Centre on Health Services and Quality of Life, Aix Marseille University, 27, boulevard Jean-Moulin, CEReSS, Marseille cedex 05, 3279, 13385, France
| | - Pascal Auquier
- Research Centre on Health Services and Quality of Life, Aix Marseille University, 27, boulevard Jean-Moulin, CEReSS, Marseille cedex 05, 3279, 13385, France
| | - Carl A Latkin
- Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, 21205, USA
| | - Melvyn W B Zhang
- Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, Singapore, Singapore
| | - Roger C M Ho
- Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119228, Singapore
- Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapore, 119077, Singapore
| | - Cyrus S H Ho
- Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119228, Singapore
| |
Collapse
|
3
|
Zhou Q, Yuan Y, Lu H, Li X, Liu Z, Gan J, Yue Z, Wu J, Sheng J, Xin L. Cancer functional states-based molecular subtypes of gastric cancer. J Transl Med 2023; 21:80. [PMID: 36739412 PMCID: PMC9899380 DOI: 10.1186/s12967-023-03921-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2022] [Accepted: 01/25/2023] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND The treatment of gastric cancer remains a challenge. METHODS We divided gastric cancer into three subtypes based on 14 cancer functional states. We investigated differences between subtypes through multi-omics data, especially at the single-cell level, which allowed us to analyze differences from the perspective of each type of cell rather than the whole. RESULTS The cluster 1 is characterized by high levels of tumor progression-related cancer functional status, worst survival outcomes, low metabolic level, high infiltration of immunosuppressive cells, high copy number variations (CNV), and low tumor mutational burden (TMB). The cluster 2 is characterized by low levels of tumor progression-related cancer functional status, favorable prognosis, moderate metabolic level, low immune cell infiltration, high CNV, and moderate TMB. Then, the cluster 3 is characterized by the high level of all cancer functional status, high metabolic level, low CNV, high TMB, high infiltration of immune cells with high cytotoxicity, and better response to immunotherapy. We also established a prognostic model based on cancer functional status and validated its robustness. CONCLUSIONS Collectively, our study identified gastric cancer subtypes and provided new insights into the clinical treatment of gastric cancer.
Collapse
Affiliation(s)
- Qi Zhou
- grid.412455.30000 0004 1756 5980Department of General Surgery, The Second Affiliated Hospital of Nanchang University, No.1 Minde Road, Donghu District, Nanchang, 330006 Jiangxi China ,grid.412455.30000 0004 1756 5980Jiangxi Province Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi China
| | - Yiwu Yuan
- grid.412455.30000 0004 1756 5980Department of General Surgery, The Second Affiliated Hospital of Nanchang University, No.1 Minde Road, Donghu District, Nanchang, 330006 Jiangxi China ,grid.412455.30000 0004 1756 5980Jiangxi Province Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi China
| | - Hao Lu
- grid.412455.30000 0004 1756 5980Department of General Surgery, The Second Affiliated Hospital of Nanchang University, No.1 Minde Road, Donghu District, Nanchang, 330006 Jiangxi China ,grid.412455.30000 0004 1756 5980Jiangxi Province Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi China
| | - Xueqin Li
- grid.412455.30000 0004 1756 5980Department of General Surgery, The Second Affiliated Hospital of Nanchang University, No.1 Minde Road, Donghu District, Nanchang, 330006 Jiangxi China ,grid.412455.30000 0004 1756 5980Nursing department, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi China
| | - Ziyang Liu
- grid.412455.30000 0004 1756 5980Department of General Surgery, The Second Affiliated Hospital of Nanchang University, No.1 Minde Road, Donghu District, Nanchang, 330006 Jiangxi China ,grid.412455.30000 0004 1756 5980Jiangxi Province Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi China
| | - Jinheng Gan
- grid.412455.30000 0004 1756 5980Department of General Surgery, The Second Affiliated Hospital of Nanchang University, No.1 Minde Road, Donghu District, Nanchang, 330006 Jiangxi China ,grid.412455.30000 0004 1756 5980Jiangxi Province Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi China
| | - Zhenqi Yue
- grid.412455.30000 0004 1756 5980Department of General Surgery, The Second Affiliated Hospital of Nanchang University, No.1 Minde Road, Donghu District, Nanchang, 330006 Jiangxi China ,grid.412455.30000 0004 1756 5980Jiangxi Province Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi China
| | - Jiping Wu
- grid.412455.30000 0004 1756 5980Department of General Surgery, The Second Affiliated Hospital of Nanchang University, No.1 Minde Road, Donghu District, Nanchang, 330006 Jiangxi China ,grid.412455.30000 0004 1756 5980Jiangxi Province Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi China
| | - Jie Sheng
- grid.412455.30000 0004 1756 5980Department of General Surgery, The Second Affiliated Hospital of Nanchang University, No.1 Minde Road, Donghu District, Nanchang, 330006 Jiangxi China ,grid.412455.30000 0004 1756 5980Jiangxi Province Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi China
| | - Lin Xin
- Department of General Surgery, The Second Affiliated Hospital of Nanchang University, No.1 Minde Road, Donghu District, Nanchang, 330006, Jiangxi, China. .,Jiangxi Province Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
| |
Collapse
|
4
|
Soo R, Mery L, Bardot A, Kanesvaran R, Keong TC, Pongnikorn D, Prasongsook N, Hutajulu SH, Irawan C, Manan AA, Thiagarajan M, Sripan P, Peters S, Storm H, Bray F, Stahel R. Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries. ESMO Open 2022; 7:100560. [PMID: 35988454 PMCID: PMC9588878 DOI: 10.1016/j.esmoop.2022.100560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2022] [Revised: 07/04/2022] [Accepted: 07/06/2022] [Indexed: 11/03/2022] Open
Abstract
BACKGROUND Lung cancer is the second most common cancer and leading cause of cancer mortality worldwide. Recent advances in molecular testing and targeted therapy have improved survival among patients with metastatic non-small-cell lung cancer (NSCLC). We sought to quantify and describe molecular testing among metastatic non-squamous NSCLC cases in selected Southeast Asian countries and describe first-line therapy chosen. PATIENTS AND METHODS A retrospective study was conducted based on incident lung cancer cases diagnosed between 2017 and 2019 in Lampang (Thailand), Penang (Malaysia), Singapore and Yogyakarta (Indonesia). Cases (n = 3413) were defined using the International Classification of Diseases for Oncology third edition. In Singapore, a clinical series obtained from the National Cancer Centre was used to identify patients, while corresponding population-based cancer registries were used elsewhere. Tumor and clinical information were abstracted by chart review according to a predefined study protocol. Molecular testing of epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) gene rearrangement, ROS1 gene rearrangement and BRAF V600 mutation was recorded. RESULTS Among 2962 cases with a specified pathological diagnosis (86.8%), most patients had non-squamous NSCLC (75.8%). For cases with staging information (92.1%), the majority presented with metastatic disease (71.3%). Overall, molecular testing rates in the 1528 patients with stage IV non-squamous NSCLC were 67.0% for EGFR, 42.3% for ALK, 39.1% for ROS1, 7.8% for BRAF and 36.1% for PD-L1. Among these patients, first-line systemic treatment included chemotherapy (25.9%), targeted therapy (35.6%) and immunotherapy (5.9%), with 31% of patients having no record of antitumor treatment. Molecular testing and the proportion of patients receiving treatment were highly heterogenous between the regions. CONCLUSIONS This first analysis of data from a clinically annotated registry for lung cancer from four settings in Southeast Asia has demonstrated the feasibility of integrating clinical data within population-based cancer registries. Our study results identify areas where further development could improve patient access to optimal treatment.
Collapse
Affiliation(s)
- R Soo
- Department of Hematology-Oncology, National University Hospital, Singapore, Singapore
| | - L Mery
- Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France
| | - A Bardot
- Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France
| | - R Kanesvaran
- Division of Medical Oncology, National Cancer Centre, Singapore, Singapore
| | - T C Keong
- Division of Medical Oncology, National Cancer Centre, Singapore, Singapore
| | - D Pongnikorn
- Cancer Registry Unit, Lampang Cancer Hospital, Lampang, Thailand
| | - N Prasongsook
- Medical Oncology Division, Department of Internal Medicine, Phramongkutklao Hospital, Bangkok, Thailand
| | - S H Hutajulu
- Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Indonesia
| | - C Irawan
- Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia
| | - A Ab Manan
- Malaysian National Cancer Registry Department, National Cancer Institute, Ministry of Health Malaysia, Putrajaya, Malaysia
| | - M Thiagarajan
- Department of Radiotherapy and Oncology, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia
| | - P Sripan
- Research Institute for Health Sciences, Chiang Mai University, Chiangmai, Thailand
| | - S Peters
- Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - H Storm
- Danish Cancer Society, Copenhagen, Denmark
| | - F Bray
- Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France
| | - R Stahel
- ETOP IBCSG Partners Foundation, Bern, Switzerland.
| |
Collapse
|
5
|
Ng SW, Syamim Syed Mohd Sobri SN, Zain RB, Kallarakkal TG, Amtha R, Wiranata Wong FA, Rimal J, Durward C, Chea C, Jayasinghe RD, Vatanasapt P, Saleha binti Ibrahim Tamin N, Cheng LC, Mazlipah binti Ismail S, Tepirou C, Ariff bin Abdul Rahman Z, Rajendran S, Kanapathy J, Liew CS, Cheong SC. Barriers to early detection and management of oral cancer in the Asia Pacific region. J Health Serv Res Policy 2022; 27:133-140. [DOI: 10.1177/13558196211053110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Objective Oral cancer is amenable to early detection but remains a prominent cause of mortality in the Asia Pacific region. This study aimed to identify barriers to early detection and management of oral cancer in the Asia Pacific region. Methods A mixed-methods approach was employed triangulating findings from a survey and focus groups. The survey was conducted among seven representative members of the Asia Pacific Oral Cancer Network (APOCNET) across six countries. Focus groups were conducted to gain deeper insights into the findings of the survey. Results The identified barriers were a lack of national cancer control strategies and cancer registries and the limited availability of trained health care professionals. Overcoming these challenges in the Asia Pacific region where resources are scarce will require collaborative partnerships in data collection and novel approaches for continuous professional training including eLearning. Further, to overcome the lack of trained health care professionals, innovative approaches to the management of oral potentially malignant lesions and oral cancer including telemedicine were suggested. Conclusion The findings of this study should be taken into account when charting national cancer control plans for oral cancer and will form the basis for future collaborative studies in evaluating effective measures to improve oral cancer detection and management in low- and middle-income countries.
Collapse
Affiliation(s)
- Sin Wi Ng
- Department of Computer System & Technology, Faculty of Computer Science & Information Technology, University of Malaya, Kuala Lumpur, Malaysia
| | - Sharifah Nur Syamim Syed Mohd Sobri
- Department of Computer System & Technology, Faculty of Computer Science & Information Technology, University of Malaya, Kuala Lumpur, Malaysia
| | - Rosnah binti Zain
- Department of Oral Pathology Oral Medicine, Faculty of Dentistry, MAHSA University, Selangor, Malaysia
| | - Thomas George Kallarakkal
- Department of Oral & Maxillofacial Clinical Sciences, Faculty of Dentistry, University of Malaya, Kuala Lumpur, Malaysia
| | - Rahmi Amtha
- Faculty of Dentistry, Trisakti University, Jakarta, Indonesia
| | | | - Jyotsna Rimal
- Department of Oral Medicine & Radiology, B.P. Koirala Institute of Health Sciences, Dharan, Nepal
| | | | | | | | - Patravoot Vatanasapt
- Department of Otorhinolaryngology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
- Cancer Unit, Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thiland
| | | | - Lai Choo Cheng
- Oral Health Programme, Ministry of Health, Kuala Lumpur, Malaysia
| | - Siti Mazlipah binti Ismail
- Department of Oral & Maxillofacial Clinical Sciences, Faculty of Dentistry, University of Malaya, Kuala Lumpur, Malaysia
| | - Chher Tepirou
- Preventive Medicine Department, Ministry of Health, Cambodia
| | | | | | | | - Chee Sun Liew
- Department of Computer System & Technology, Faculty of Computer Science & Information Technology, University of Malaya, Kuala Lumpur, Malaysia
- Data Intensive Computing Centre, Research Management & Innovation Complex, University of Malaya, Kuala Lumpur, Malaysia
- Centre for Data Science, University of Malaya, Kuala Lumpur, Malaysia
| | - Sok Ching Cheong
- Department of Oral & Maxillofacial Clinical Sciences, Faculty of Dentistry, University of Malaya, Kuala Lumpur, Malaysia
- Digital Health, Cancer Research Malaysia, Subang Jaya, Malaysia
| |
Collapse
|
6
|
Allen LN, Wild CEK, Loffreda G, Kak M, Aghilla M, Emahbes T, Bonyani A, Hatefi A, Herbst C, El Saeh HM. Non-communicable disease policy implementation in Libya: A mixed methods assessment. PLOS GLOBAL PUBLIC HEALTH 2022; 2:e0000615. [PMID: 36962549 PMCID: PMC10021530 DOI: 10.1371/journal.pgph.0000615] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/03/2022] [Accepted: 10/09/2022] [Indexed: 11/12/2022]
Abstract
The Libyan Ministry of Health is keen to understand how it can introduce policies to protect its population from non-communicable diseases (NCDs). We aimed to perform an implementation research assessment of the current situation, including challenges and opportunities. We used an explanatory sequential mixed methods design. We started with a quantitative assessment of NCD policy performance based on review of the WHO NCD Progress Monitor Reports. Once we had identified Libya's NCD policy gaps we performed a systematic review to identify international lessons around barriers and successful strategies for the policies Libya has not yet implemented. Finally, we performed a series of key stakeholder interviews with senior policymakers to explore their perspectives around promising policy actions. We used a realist paradigm, methods triangulation, and a joint display to synthesise the interpretation of our findings and develop recommendations. Libya has not fully implemented any of the recommended policies for diet, physical activity, primary care guidelines & therapeutics, or data collection, targets & surveillance. It does not have robust tobacco policies in place. Evidence from the international literature and policymaker interviews emphasised the centrality of according strong political leadership, governance structures, multisectoral engagement, and adequate financing to policy development activities. Libya's complex political and security situation are major barriers for policy implementation. Whilst some policies will be very challenging to develop and deploy, there are a number of simple policy actions that could be implemented with minimum effort; from inviting WHO to conduct a second STEPS survey, to signing the international code on breast-milk substitutes. Like many other fragile and conflict-affected states, Libya has not accorded NCDs the policy attention they demand. Whilst strong high-level leadership is the ultimate key to providing adequate protections, there are a range of simple measures that can be implemented with relative ease.
Collapse
Affiliation(s)
- Luke N Allen
- Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Cervantée E K Wild
- Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom
| | - Giulia Loffreda
- Institute for Global Health and Development, Queen Margaret University, Edinburgh, Scotland
| | - Mohini Kak
- World Bank Middle East and North Africa, Tunisia
| | | | | | | | - Arian Hatefi
- World Bank Middle East and North Africa, Washington, DC, United States of America
| | | | - Haider M El Saeh
- Libya National Centre for Disease Control, Tajoura, Libya
- University of Tripoli, Tripoli, Libya
| |
Collapse
|
7
|
Jailobaeva K, Falconer J, Loffreda G, Arakelyan S, Witter S, Ager A. An analysis of policy and funding priorities of global actors regarding noncommunicable disease in low- and middle-income countries. Global Health 2021; 17:68. [PMID: 34187499 PMCID: PMC8240078 DOI: 10.1186/s12992-021-00713-4] [Citation(s) in RCA: 35] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2021] [Accepted: 06/08/2021] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Noncommunicable diseases (NCDs), including mental health, have become a major concern in low- and middle-income countries. Despite increased attention to them over the past decade, progress toward addressing NCDs has been slow. A lack of bold policy commitments has been suggested as one of the contributors to limited progress in NCD prevention and management. However, the policies of key global actors (bilateral, multilateral, and not-for-profit organisations) have been understudied. METHODS This study aimed to map the key global actors investing in action regarding NCDs and review their policies to examine the articulation of priorities regarding NCDs. Narrative synthesis of 70 documents and 31 policy papers was completed, and related to data collated from the Global Health Data Visualisation Tool. RESULTS In 2019 41% of development assistance for health committed to NCDs came from private philanthropies, while that for other global health priorities from this source was just 20%. Through a range of channels, bilateral donors were the other major source of NCD funding (contributing 41% of NCD funding). The UK and the US were the largest bilateral investors in NCDs, each contributing 8%. However, NCDs are still under-prioritised within bilateral portfolios - receiving just 0.48% of US funding and 1.66% of the UK. NGOs were the key channels of funding for NCDs, spending 48% of the funds from donors in 2019. The reviewed literature generally focused on NCD policies of WHO, with policies of multilateral and bilateral donors given limited attention. The analysis of policies indicated a limited prioritisation of NCDs in policy documents. NCDs are framed in the policies as a barrier to economic growth, poverty reduction, and health system sustainability. Bilateral donors prioritise prevention, while multilateral actors offer policy options for NCD prevention and care. Even where stated as a priority, however, funding allocations are not aligned. CONCLUSION The growing threat of NCDs and their drivers are increasingly recognised. However, global actors' policy priorities and funding allocations need to align better to address these NCD threats. Given the level of their investment and engagement, more research is needed into the role of private philanthropies and NGOs in this area.
Collapse
Affiliation(s)
- Kanykey Jailobaeva
- Institute for Global Health and Development, Queen Margaret University, Edinburgh, EH21 6UU UK
| | - Jennifer Falconer
- Institute for Global Health and Development, Queen Margaret University, Edinburgh, EH21 6UU UK
| | - Giulia Loffreda
- Institute for Global Health and Development, Queen Margaret University, Edinburgh, EH21 6UU UK
| | - Stella Arakelyan
- Institute for Global Health and Development, Queen Margaret University, Edinburgh, EH21 6UU UK
| | - Sophie Witter
- Institute for Global Health and Development, Queen Margaret University, Edinburgh, EH21 6UU UK
| | - Alastair Ager
- Institute for Global Health and Development, Queen Margaret University, Edinburgh, EH21 6UU UK
| |
Collapse
|
8
|
Li L, Wang X. Identification of gastric cancer subtypes based on pathway clustering. NPJ Precis Oncol 2021; 5:46. [PMID: 34079012 PMCID: PMC8172826 DOI: 10.1038/s41698-021-00186-z] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2020] [Accepted: 05/13/2021] [Indexed: 02/06/2023] Open
Abstract
Gastric cancer (GC) is highly heterogeneous in the stromal and immune microenvironment, genome instability (GI), and oncogenic signatures. However, a classification of GC by combining these features remains lacking. Using the consensus clustering algorithm, we clustered GCs based on the activities of 15 pathways associated with immune, DNA repair, oncogenic, and stromal signatures in three GC datasets. We identified three GC subtypes: immunity-deprived (ImD), stroma-enriched (StE), and immunity-enriched (ImE). ImD showed low immune infiltration, high DNA damage repair activity, high tumor aneuploidy level, high intratumor heterogeneity (ITH), and frequent TP53 mutations. StE displayed high stromal signatures, low DNA damage repair activity, genomic stability, low ITH, and poor prognosis. ImE had strong immune infiltration, high DNA damage repair activity, high tumor mutation burden, prevalence of microsatellite instability, frequent ARID1A mutations, elevated PD-L1 expression, and favorable prognosis. Based on the expression levels of four genes (TAP2, SERPINB5, LTBP1, and LAMC1) in immune, DNA repair, oncogenic, and stromal pathways, we developed a prognostic model (IDOScore). The IDOScore was an adverse prognostic factor and correlated inversely with immunotherapy response in cancer. Our identification of new GC subtypes provides novel insights into tumor biology and has potential clinical implications for the management of GCs.
Collapse
Affiliation(s)
- Lin Li
- Biomedical Informatics Research Lab, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China
- Cancer Genomics Research Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China
- Big Data Research Institute, China Pharmaceutical University, Nanjing, China
| | - Xiaosheng Wang
- Biomedical Informatics Research Lab, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
- Cancer Genomics Research Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
- Big Data Research Institute, China Pharmaceutical University, Nanjing, China.
| |
Collapse
|
9
|
Pham T, Bui L, Kim G, Hoang D, Tran T, Hoang M. Cancers in Vietnam-Burden and Control Efforts: A Narrative Scoping Review. Cancer Control 2019; 26:1073274819863802. [PMID: 31319695 PMCID: PMC6643189 DOI: 10.1177/1073274819863802] [Citation(s) in RCA: 48] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2019] [Revised: 06/04/2019] [Accepted: 06/18/2019] [Indexed: 01/19/2023] Open
Abstract
Although the burden of cancer is rapidly growing in Vietnam, there was no up-to-date review that describes cancer burden and control in Vietnam throughout the literature. By identifying various risk factors, means of prevention, and methods for early detection, this review seeks to systematically summarize the evidence for the future planning and management of cancer occurrence in Vietnam. Additionally, this report aims to identify improvements which are necessary for the treatment and palliative care of patients with cancer in Vietnam. We employed a hybrid approach including both a scoping review and narrative synthesis for this study. Information was identified, extracted, and charted from various sources, which include international and domestically published studies, in addition to gray literature. Our results illustrate that the burden of cancer in Vietnam has tripled in the past 30 years, and this situation could be partly explained by the growing prevalence of both old and new risk factors. Besides hepatitis B virus, various other important risk factors such as human papilloma virus, tobacco usage, physical inactivity, and improper diets are still not under control in Vietnam. There is presently a lack of national cancer screening programs, and the capacity of cancer care services could not maintain pace with the demands of a rapidly increasing Vietnamese population. Overall, policy frameworks for cancer control in Vietnam are in place, but there is still a lack of proper financing and governing models necessary to support a sustainable program. In conclusion, Cancer and its associated consequences are both persistent and emerging problems in Vietnam, and the results of cancer control programs are limited. A comprehensive and evidence-based approach toward the prevention and treatment of cancer should be the future direction for Vietnam.
Collapse
Affiliation(s)
- Tung Pham
- Department of Physiology, Hanoi Medical University, Hanoi,
Vietnam
- Center for Population Health Science, Hanoi University of Public
Health, Hanoi, Vietnam
| | - Linh Bui
- Center for Population Health Science, Hanoi University of Public
Health, Hanoi, Vietnam
| | - Giang Kim
- Department of Health Education, Hanoi Medical University, Hanoi,
Vietnam
| | - Dong Hoang
- Vietnam National Cancer Institute, National Cancer Hospital, Hanoi,
Vietnam
| | - Thuan Tran
- Vietnam National Cancer Institute, National Cancer Hospital, Hanoi,
Vietnam
| | - Minh Hoang
- Department of Health Economics, Hanoi University of Public Health,
Hanoi, Vietnam
| |
Collapse
|
10
|
Phull AR, Kim SJ. Undaria pinnatifida a Rich Marine Reservoir of Nutritional and Pharmacological Potential: Insights into Growth Signaling and Apoptosis Mechanisms in Cancer. Nutr Cancer 2018; 70:956-970. [PMID: 30616379 DOI: 10.1080/01635581.2018.1490449] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2017] [Accepted: 06/04/2018] [Indexed: 02/04/2023]
Abstract
Seaweeds are an important part of diet consumed in a different part of the world such as New Zealand, Ireland, Wales, and Asian countries including Korea, China, and Japan. In addition, seaweed is nutritious sources possessing health improving effects and therapeutic potential. Recently, one of the widely eaten seaweed species Undaria pinnatifida (U. pinnatifida) has got much attention because of its pharmacological properties for the prevention of various ailments, including cancer, inflammation, and other diseases. It is rich in all essential amino acids, physiologically significant fatty acids, vitamins, minerals, and has a variety of bioactive constituents which include fucoidan, carotenoids, and fucoxanthin. The present study reviews the nutritional aspects, key bioactivities specifically focusing on anticancer potential along with apoptosis and growth signaling mechanisms of U. pinnatifida or its constituents. It exhibited anticancer effects both in vitro and in vivo studies in a variety of experimental models. Due to a variety of pharmacological properties of U. pinnatifida can not only fulfilling nutritional necessities, but it can be used for treating, curing and preventing cancer.
Collapse
Affiliation(s)
- Abdul Rehman Phull
- a Department of Biological Sciences, College of Natural Sciences , Kongju National University , Chungnam , Republic of Korea
- b Department of Biochemistry , Shah Abdul Latif University , Khairpur , Sindh , Pakistan
| | - Song Ja Kim
- a Department of Biological Sciences, College of Natural Sciences , Kongju National University , Chungnam , Republic of Korea
| |
Collapse
|
11
|
San TH, Fujisawa M, Fushimi S, Soe L, Min NW, Yoshimura T, Ohara T, Yee MM, Oda S, Matsukawa A. Molecular Subtypes of Breast Cancers from Myanmar Women: A Study of 91 Cases at Two Pathology Centers. Asian Pac J Cancer Prev 2017; 18:1617-1621. [PMID: 28670879 PMCID: PMC6373824 DOI: 10.22034/apjcp.2017.18.6.1617] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Background: Breast cancer is the most common cancer in Myanmar women. Revealing the hormonal receptor
status, human epidermal growth factor receptor 2 (HER2) and Ki-67 expression is useful for estimating patient
prognosis as well as determination of treatment strategy. However, immunohistochemical features and classification of
molecular subtypes in breast cancers from Myanmar remain unknown. Methods: The clinicopathological features of
91 breast cancers from Myanmar women were examined. Immunohistochemistry was performed on tissue specimens
with antibodies to estrogen receptor (ER), progesterone receptor (PgR), HER2, Ki-67, cytokeratin (CK)5/6 and CK14.
Immunohistochemistry-based molecular subtyping was conducted. Results: Breast cancers in Myanmar women were
relatively large, high grade with frequent metastatic lymph nodes. Of the 91 patients, tumors with ER positive, PgR
positive, and HER2 positive were 57.1%, 37.4%, and 28.6%, respectively. The most prevalent subtype was luminal B
(HER2-) (39.6%), followed by HER2 (22.0%), triple negative (TN)-basal-like (12.1%), luminal A (11.0%), TN-null
(8.8%) and luminal B (HER2+) (6.6%). The mean Ki-67 expression of 91 cases was 33.9% (33.9% ± 19.2%) and the
median was 28% (range; 4%-90%). The mean Ki-67 expression of luminal A, luminal B, HER2 and TN-basal-like/
null was 7%, 30%, 40%, and 57%/43%, respectively. A higher Ki-67 expression significantly correlated with a higher
grade, larger size and higher stage of malignancy. Conclusions: We, for the first time, investigated the histopathological
features of breast cancers from Myanmar women. Myanmar breast cancers appeared to be aggressive in nature, as
evidenced by high frequency of poor-prognosis subtypes with high level of Ki-67 expression.
Collapse
Affiliation(s)
- Thar Htet San
- Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
San TH, Fujisawa M, Fushimi S, Yoshimura T, Ohara T, Soe L, Min NW, Kyaw O, Yang X, Matsukawa A. Low prevalence of human mammary tumor virus (HMTV) in breast cancer patients from Myanmar. Infect Agent Cancer 2017; 12:20. [PMID: 28413435 PMCID: PMC5389013 DOI: 10.1186/s13027-017-0130-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2017] [Accepted: 04/05/2017] [Indexed: 01/19/2023] Open
Abstract
BACKGROUND Human mammary tumor virus (HMTV) is 90-95% homologous to mouse mammary tumor virus (MMTV), one of the causal agents of murine mammary tumors. HMTV (MMTV-like) sequences were reported to be present in human breast cancers from several populations with a prevalence range of 0-78%; however, the prevalence of HMTV in breast cancers from Myanmar remains unknown. METHODS Fifty-eight breast cancer samples from Myanmar women were examined in this study. DNA was isolated from formalin-fixed paraffin-embedded specimens, and HMTV envelope sequences were detected by semi-nested PCR. The sequence of the PCR products was also confirmed. RESULTS Only 1.7% (1 of 58) of the breast cancers were positive for HMTV, and the sequence of PCR products was 98.9% identical to the reference HMTV sequence (GenBank accession No. AF243039). The tumor with HMTV was grade III invasive ductal carcinoma, 7.0 cm in size with lymph node metastasis (T3, N1, M0). CONCLUSIONS We, for the first time, investigated the presence of HMTV in Myanmar breast cancer patients. In accordance with other Asian studies, the prevalence of HMTV in Myanmar was quite low, supporting the hypothesis that Asian breast cancers have different etiologies than in Western countries, where HMTV is more prevalent.
Collapse
Affiliation(s)
- Thar Htet San
- Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata, Okayama, 700-8558 Japan
| | - Masayoshi Fujisawa
- Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata, Okayama, 700-8558 Japan
| | - Soichiro Fushimi
- Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata, Okayama, 700-8558 Japan
- Department of Pathology, Himeji Red Cross Hospital, Himeji, Japan
| | - Teizo Yoshimura
- Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata, Okayama, 700-8558 Japan
| | - Toshiaki Ohara
- Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata, Okayama, 700-8558 Japan
| | - Lamin Soe
- Department of Pathology, Myeik General Hospital, Myeik, Myanmar
| | - Ngu Wah Min
- Department of Pathology, Sakura Specialist Hospital, Yangon, Myanmar
| | - Ohnmar Kyaw
- Immunology Research Division, Department of Medical Research, Yangon, Myanmar
| | - Xu Yang
- Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata, Okayama, 700-8558 Japan
| | - Akihiro Matsukawa
- Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata, Okayama, 700-8558 Japan
| |
Collapse
|
13
|
Heidarli E, Dadashzadeh S, Haeri A. State of the Art of Stimuli-Responsive Liposomes for Cancer Therapy. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH : IJPR 2017; 16:1273-1304. [PMID: 29552041 PMCID: PMC5843293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 10/29/2022]
Abstract
Specific delivery of therapeutic agents to solid tumors and their bioavailability at the target site are the most clinically important and challenging goals in cancer therapy. Liposomes are promising nanocarriers and have been well investigated for cancer therapy. In spite of preferred accumulation in tumors via the enhanced permeability and retention (EPR) effect, inefficient drug release at the target site and endosomal entrapment of long circulating liposomes are very important obstacles for achieving maximum anticancer efficacy. Thus, additional strategies such as stimulus-sensitive drug release are necessary to improve efficacy. Stimuli-sensitive liposomes are stable in blood circulation, however, activated by responding to external or internal stimuli and control the cargo release at the target site. This review focuses on state of the art of stimuli-responsive liposomes. Both external stimuli-responsive liposomes, including hyperthermia (HT), magnetic, light, and ultrasound-sensitive liposomes and internal stimuli (pH, reduction, and enzyme) responsive liposomes are covered.
Collapse
Affiliation(s)
- Elmira Heidarli
- Department of Pharmaceutics, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
| | - Simin Dadashzadeh
- Department of Pharmaceutics, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
| | - Azadeh Haeri
- Department of Pharmaceutics, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ,Protein Technology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.,Corresponding author: E-mail:
| |
Collapse
|
14
|
Mamyrbayev A, Dyussembayeva N, Ibrayeva L, Satenova Z, Tulyayeva A, Kireyeva N, Zholmukhamedova D, Rybalkina D, Yeleuov G, Yeleuov A. Features of Malignancy Prevalence among Children in the Aral Sea Region. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION : APJCP 2016; 17:5217-5221. [PMID: 28125864 PMCID: PMC5454661 DOI: 10.22034/apjcp.2016.17.12.5217] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Objective: A study of primary cancer morbidity among children and subsequent calculation of average annual incidence were carried out for boys and girls, and young men and women in Kazakhstan. Methods: The investigated population lived in three areas of the Aral Sea region: designated catastrophe (Aral, Kazalt, Shalkar regions), crisis (Zhalagash, Karmakshy, Shiely regions), pre-crisis (Irgiz, Arys, Ulytau regions). Zhanaarka region of Karaganda oblast was applied as a control. Parameters were retrospective analyzed for the 10 years from 2004 to 2013. Result: The results indicate that indices of children cancer morbidity were slightly higher in the Aral Sea region than in the control district, but they were comparable with similar data from studies in other regions. In all areas of the Aral Sea region, except for Ulytau, primary cancer morbidity exceeded the control level by 1.3-2.7 times (4.7%000). Hematological malignancies, including solid tumors - tumors of musculoskeletal system and skin, digestive system, brain and central nervous system predominated. Stress levels in zones of the Aral Sea region were slightly higher in the crisis zone than in the catastrophe zone that can be explained by the phenomenon of wave-like dynamics of disease growth risk. Gender differences in characteristics of malignancy formation were not more pronounced in the studied region. Conclusion: Indices of children cancer are slightly higher in the Aral Sea region than in the control area of Kazakhstan, but they are comparable to results for other regions.
Collapse
Affiliation(s)
- Arstan Mamyrbayev
- West Kazakhstan branch of & ldquo; National Centre for Occupational Health and Occupational Diseases& rdquo; MHSD of Kazakhstan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Molecular Phylogenetic Screening of Withania somnifera Relative From Indonesia Based on Internal Transcribed Spacer Region. HAYATI JOURNAL OF BIOSCIENCES 2016. [DOI: 10.1016/j.hjb.2016.02.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
16
|
Budiarto BR, Desriani. Detection of HER2 Gene Polymorphism in Breast Cancer: PCR Optimization Study. Sci Pharm 2016; 84:103-11. [PMID: 27110502 PMCID: PMC4839552 DOI: 10.3797/scipharm.isp.2015.03] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2015] [Accepted: 12/15/2015] [Indexed: 11/22/2022] Open
Abstract
Cancers are the most deadly diseases in the world and their incidences continue to increase over time. Particularly, breast cancer in females places 1st rank among other types of cancers in term of cancer cases (23%) and death incidence (14%). Recent findings support the correlation between Ile655Val SNP in the HER2 gene with breast cancer risk. Moreover, the Ile655Val HER2 gene polymorphism could be a predictive factor in a neoadjuvant therapy setting. Precise detection of the Ile655Val HER2 gene SNP in early breast cancer patients will be beneficial in designing the most suitable treatment and in increasing the efficacy of anticancer drugs. Here we develop a rapid and inexpensive method for Ile655Val SNP detection in the HER2 gene based on allele-specific PCR technology. Two forward primers and one common reverse primer were designed to anneal specifically either on the HER2 gene fragment containing the GG genotype or to the HER2 gene fragment containing the AA genotype where one of these primers had been added with poly-GC at 5’ upstream. Moreover, to increase discrimination level, mismatch bases at the SNP site and the 3rd base of each forward primers from 3’end were added. To test the performance of the designed primers in discriminating a polymorphism and its annealing temperature, breast cancer specimen-derived genomic DNA (with GG genotype) and pGEM_HER2/AA (with AA genotype) were used as templates in the PCR reaction. The optimal annealing temperature for SNP detection was at 51.5°C as showed by the appearance of a 150 base pair (bp) band as AA genotype (pGEM_HER2/AA template), 116bp band as GG genotype (genomic DNA template), and both types of bands as AG genotype (mix of pGEM_HER2/AA and genomic DNA template). Allelic types of breast cancer patients were also determined using this optimized method compared to sanger sequencing. The 100% accordance was shown for all types of genotypes in both methods. The allele-specific PCR in this study may have application in determining polymorphisms of the breast cancers-originated Ile655Val HER2 gene.
Collapse
Affiliation(s)
- Bugi Ratno Budiarto
- Research Center for Biotechnology, Indonesian Institute of Sciences (LIPI), Jalan Raya Bogor Km. 46, Cibinong 16911, Indonesia
| | - Desriani
- Research Center for Biotechnology, Indonesian Institute of Sciences (LIPI), Jalan Raya Bogor Km. 46, Cibinong 16911, Indonesia
| |
Collapse
|
17
|
Rodriguez-Galindo C, Friedrich P, Alcasabas P, Antillon F, Banavali S, Castillo L, Israels T, Jeha S, Harif M, Sullivan MJ, Quah TC, Patte C, Pui CH, Barr R, Gross T. Toward the Cure of All Children With Cancer Through Collaborative Efforts: Pediatric Oncology As a Global Challenge. J Clin Oncol 2015; 33:3065-73. [PMID: 26304881 DOI: 10.1200/jco.2014.60.6376] [Citation(s) in RCA: 268] [Impact Index Per Article: 29.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
Advances in the treatment of childhood cancers have resulted in part from the development of national and international collaborative initiatives that have defined biologic determinants and generated risk-adapted therapies that maximize cure while minimizing acute and long-term effects. Currently, more than 80% of children with cancer who are treated with modern multidisciplinary treatments in developed countries are cured; however, of the approximately 160,000 children and adolescents who are diagnosed with cancer every year worldwide, 80% live in low- and middle-income countries (LMICs), where access to quality care is limited and chances of cure are low. In addition, the disease burden is not fully known because of the lack of population-based cancer registries in low-resource countries. Regional and ethnic variations in the incidence of the different childhood cancers suggest unique interactions between genetic and environmental factors that could provide opportunities for etiologic research. Regional collaborative initiatives have been developed in Central and South America and the Caribbean, Africa, the Middle East, Asia, and Oceania. These initiatives integrate regional capacity building, education of health care providers, implementation of intensity-graduated treatments, and establishment of research programs that are adjusted to local capacity and local needs. Together, the existing consortia and regional networks operating in LMICs have the potential to reach out to almost 60% of all children with cancer worldwide. In summary, childhood cancer burden has been shifted toward LMICs and, for that reason, global initiatives directed at pediatric cancer care and control are needed. Regional networks aiming to build capacity while incorporating research on epidemiology, health services, and outcomes should be supported.
Collapse
Affiliation(s)
- Carlos Rodriguez-Galindo
- Carlos Rodriguez-Galindo and Paola Friedrich, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Patricia Alcasabas, Philippines General Hospital, Manila, Philippines; Federico Antillon, Unidad Nacional de Oncología Pediátrica, and Francisco Marroquín Medical School, Guatemala City, Guatemala; Shripad Banavali, Tata Memorial Hospital, Mumbai, India; Luis Castillo, Hospital Pereira Rossell, Montevideo, Uruguay; Trijn Israels, Vrije Universiteit Medical Center, Amsterdam, the Netherlands; Sima Jeha and Ching-Hon Pui, St Jude Children's Research Hospital, Memphis, TN; Mhammed Harif, Centre Hospitalier Universitaire Mohammed VI, Marrakech, Morocco; Michael J. Sullivan, Royal Children's Hospital, Melbourne, Australia; Thuan Chong Quah, National University Health System, Singapore; Catherine Patte, Institute Gustave-Roussy, Villejuif, France; Ronald Barr, McMaster University and McMaster Children's Hospital, Hamilton, ON, Canada; and Thomas Gross, National Cancer Institute Center for Global Health, Bethesda, MD.
| | - Paola Friedrich
- Carlos Rodriguez-Galindo and Paola Friedrich, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Patricia Alcasabas, Philippines General Hospital, Manila, Philippines; Federico Antillon, Unidad Nacional de Oncología Pediátrica, and Francisco Marroquín Medical School, Guatemala City, Guatemala; Shripad Banavali, Tata Memorial Hospital, Mumbai, India; Luis Castillo, Hospital Pereira Rossell, Montevideo, Uruguay; Trijn Israels, Vrije Universiteit Medical Center, Amsterdam, the Netherlands; Sima Jeha and Ching-Hon Pui, St Jude Children's Research Hospital, Memphis, TN; Mhammed Harif, Centre Hospitalier Universitaire Mohammed VI, Marrakech, Morocco; Michael J. Sullivan, Royal Children's Hospital, Melbourne, Australia; Thuan Chong Quah, National University Health System, Singapore; Catherine Patte, Institute Gustave-Roussy, Villejuif, France; Ronald Barr, McMaster University and McMaster Children's Hospital, Hamilton, ON, Canada; and Thomas Gross, National Cancer Institute Center for Global Health, Bethesda, MD
| | - Patricia Alcasabas
- Carlos Rodriguez-Galindo and Paola Friedrich, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Patricia Alcasabas, Philippines General Hospital, Manila, Philippines; Federico Antillon, Unidad Nacional de Oncología Pediátrica, and Francisco Marroquín Medical School, Guatemala City, Guatemala; Shripad Banavali, Tata Memorial Hospital, Mumbai, India; Luis Castillo, Hospital Pereira Rossell, Montevideo, Uruguay; Trijn Israels, Vrije Universiteit Medical Center, Amsterdam, the Netherlands; Sima Jeha and Ching-Hon Pui, St Jude Children's Research Hospital, Memphis, TN; Mhammed Harif, Centre Hospitalier Universitaire Mohammed VI, Marrakech, Morocco; Michael J. Sullivan, Royal Children's Hospital, Melbourne, Australia; Thuan Chong Quah, National University Health System, Singapore; Catherine Patte, Institute Gustave-Roussy, Villejuif, France; Ronald Barr, McMaster University and McMaster Children's Hospital, Hamilton, ON, Canada; and Thomas Gross, National Cancer Institute Center for Global Health, Bethesda, MD
| | - Federico Antillon
- Carlos Rodriguez-Galindo and Paola Friedrich, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Patricia Alcasabas, Philippines General Hospital, Manila, Philippines; Federico Antillon, Unidad Nacional de Oncología Pediátrica, and Francisco Marroquín Medical School, Guatemala City, Guatemala; Shripad Banavali, Tata Memorial Hospital, Mumbai, India; Luis Castillo, Hospital Pereira Rossell, Montevideo, Uruguay; Trijn Israels, Vrije Universiteit Medical Center, Amsterdam, the Netherlands; Sima Jeha and Ching-Hon Pui, St Jude Children's Research Hospital, Memphis, TN; Mhammed Harif, Centre Hospitalier Universitaire Mohammed VI, Marrakech, Morocco; Michael J. Sullivan, Royal Children's Hospital, Melbourne, Australia; Thuan Chong Quah, National University Health System, Singapore; Catherine Patte, Institute Gustave-Roussy, Villejuif, France; Ronald Barr, McMaster University and McMaster Children's Hospital, Hamilton, ON, Canada; and Thomas Gross, National Cancer Institute Center for Global Health, Bethesda, MD
| | - Shripad Banavali
- Carlos Rodriguez-Galindo and Paola Friedrich, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Patricia Alcasabas, Philippines General Hospital, Manila, Philippines; Federico Antillon, Unidad Nacional de Oncología Pediátrica, and Francisco Marroquín Medical School, Guatemala City, Guatemala; Shripad Banavali, Tata Memorial Hospital, Mumbai, India; Luis Castillo, Hospital Pereira Rossell, Montevideo, Uruguay; Trijn Israels, Vrije Universiteit Medical Center, Amsterdam, the Netherlands; Sima Jeha and Ching-Hon Pui, St Jude Children's Research Hospital, Memphis, TN; Mhammed Harif, Centre Hospitalier Universitaire Mohammed VI, Marrakech, Morocco; Michael J. Sullivan, Royal Children's Hospital, Melbourne, Australia; Thuan Chong Quah, National University Health System, Singapore; Catherine Patte, Institute Gustave-Roussy, Villejuif, France; Ronald Barr, McMaster University and McMaster Children's Hospital, Hamilton, ON, Canada; and Thomas Gross, National Cancer Institute Center for Global Health, Bethesda, MD
| | - Luis Castillo
- Carlos Rodriguez-Galindo and Paola Friedrich, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Patricia Alcasabas, Philippines General Hospital, Manila, Philippines; Federico Antillon, Unidad Nacional de Oncología Pediátrica, and Francisco Marroquín Medical School, Guatemala City, Guatemala; Shripad Banavali, Tata Memorial Hospital, Mumbai, India; Luis Castillo, Hospital Pereira Rossell, Montevideo, Uruguay; Trijn Israels, Vrije Universiteit Medical Center, Amsterdam, the Netherlands; Sima Jeha and Ching-Hon Pui, St Jude Children's Research Hospital, Memphis, TN; Mhammed Harif, Centre Hospitalier Universitaire Mohammed VI, Marrakech, Morocco; Michael J. Sullivan, Royal Children's Hospital, Melbourne, Australia; Thuan Chong Quah, National University Health System, Singapore; Catherine Patte, Institute Gustave-Roussy, Villejuif, France; Ronald Barr, McMaster University and McMaster Children's Hospital, Hamilton, ON, Canada; and Thomas Gross, National Cancer Institute Center for Global Health, Bethesda, MD
| | - Trijn Israels
- Carlos Rodriguez-Galindo and Paola Friedrich, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Patricia Alcasabas, Philippines General Hospital, Manila, Philippines; Federico Antillon, Unidad Nacional de Oncología Pediátrica, and Francisco Marroquín Medical School, Guatemala City, Guatemala; Shripad Banavali, Tata Memorial Hospital, Mumbai, India; Luis Castillo, Hospital Pereira Rossell, Montevideo, Uruguay; Trijn Israels, Vrije Universiteit Medical Center, Amsterdam, the Netherlands; Sima Jeha and Ching-Hon Pui, St Jude Children's Research Hospital, Memphis, TN; Mhammed Harif, Centre Hospitalier Universitaire Mohammed VI, Marrakech, Morocco; Michael J. Sullivan, Royal Children's Hospital, Melbourne, Australia; Thuan Chong Quah, National University Health System, Singapore; Catherine Patte, Institute Gustave-Roussy, Villejuif, France; Ronald Barr, McMaster University and McMaster Children's Hospital, Hamilton, ON, Canada; and Thomas Gross, National Cancer Institute Center for Global Health, Bethesda, MD
| | - Sima Jeha
- Carlos Rodriguez-Galindo and Paola Friedrich, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Patricia Alcasabas, Philippines General Hospital, Manila, Philippines; Federico Antillon, Unidad Nacional de Oncología Pediátrica, and Francisco Marroquín Medical School, Guatemala City, Guatemala; Shripad Banavali, Tata Memorial Hospital, Mumbai, India; Luis Castillo, Hospital Pereira Rossell, Montevideo, Uruguay; Trijn Israels, Vrije Universiteit Medical Center, Amsterdam, the Netherlands; Sima Jeha and Ching-Hon Pui, St Jude Children's Research Hospital, Memphis, TN; Mhammed Harif, Centre Hospitalier Universitaire Mohammed VI, Marrakech, Morocco; Michael J. Sullivan, Royal Children's Hospital, Melbourne, Australia; Thuan Chong Quah, National University Health System, Singapore; Catherine Patte, Institute Gustave-Roussy, Villejuif, France; Ronald Barr, McMaster University and McMaster Children's Hospital, Hamilton, ON, Canada; and Thomas Gross, National Cancer Institute Center for Global Health, Bethesda, MD
| | - Mhammed Harif
- Carlos Rodriguez-Galindo and Paola Friedrich, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Patricia Alcasabas, Philippines General Hospital, Manila, Philippines; Federico Antillon, Unidad Nacional de Oncología Pediátrica, and Francisco Marroquín Medical School, Guatemala City, Guatemala; Shripad Banavali, Tata Memorial Hospital, Mumbai, India; Luis Castillo, Hospital Pereira Rossell, Montevideo, Uruguay; Trijn Israels, Vrije Universiteit Medical Center, Amsterdam, the Netherlands; Sima Jeha and Ching-Hon Pui, St Jude Children's Research Hospital, Memphis, TN; Mhammed Harif, Centre Hospitalier Universitaire Mohammed VI, Marrakech, Morocco; Michael J. Sullivan, Royal Children's Hospital, Melbourne, Australia; Thuan Chong Quah, National University Health System, Singapore; Catherine Patte, Institute Gustave-Roussy, Villejuif, France; Ronald Barr, McMaster University and McMaster Children's Hospital, Hamilton, ON, Canada; and Thomas Gross, National Cancer Institute Center for Global Health, Bethesda, MD
| | - Michael J Sullivan
- Carlos Rodriguez-Galindo and Paola Friedrich, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Patricia Alcasabas, Philippines General Hospital, Manila, Philippines; Federico Antillon, Unidad Nacional de Oncología Pediátrica, and Francisco Marroquín Medical School, Guatemala City, Guatemala; Shripad Banavali, Tata Memorial Hospital, Mumbai, India; Luis Castillo, Hospital Pereira Rossell, Montevideo, Uruguay; Trijn Israels, Vrije Universiteit Medical Center, Amsterdam, the Netherlands; Sima Jeha and Ching-Hon Pui, St Jude Children's Research Hospital, Memphis, TN; Mhammed Harif, Centre Hospitalier Universitaire Mohammed VI, Marrakech, Morocco; Michael J. Sullivan, Royal Children's Hospital, Melbourne, Australia; Thuan Chong Quah, National University Health System, Singapore; Catherine Patte, Institute Gustave-Roussy, Villejuif, France; Ronald Barr, McMaster University and McMaster Children's Hospital, Hamilton, ON, Canada; and Thomas Gross, National Cancer Institute Center for Global Health, Bethesda, MD
| | - Thuan Chong Quah
- Carlos Rodriguez-Galindo and Paola Friedrich, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Patricia Alcasabas, Philippines General Hospital, Manila, Philippines; Federico Antillon, Unidad Nacional de Oncología Pediátrica, and Francisco Marroquín Medical School, Guatemala City, Guatemala; Shripad Banavali, Tata Memorial Hospital, Mumbai, India; Luis Castillo, Hospital Pereira Rossell, Montevideo, Uruguay; Trijn Israels, Vrije Universiteit Medical Center, Amsterdam, the Netherlands; Sima Jeha and Ching-Hon Pui, St Jude Children's Research Hospital, Memphis, TN; Mhammed Harif, Centre Hospitalier Universitaire Mohammed VI, Marrakech, Morocco; Michael J. Sullivan, Royal Children's Hospital, Melbourne, Australia; Thuan Chong Quah, National University Health System, Singapore; Catherine Patte, Institute Gustave-Roussy, Villejuif, France; Ronald Barr, McMaster University and McMaster Children's Hospital, Hamilton, ON, Canada; and Thomas Gross, National Cancer Institute Center for Global Health, Bethesda, MD
| | - Catherine Patte
- Carlos Rodriguez-Galindo and Paola Friedrich, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Patricia Alcasabas, Philippines General Hospital, Manila, Philippines; Federico Antillon, Unidad Nacional de Oncología Pediátrica, and Francisco Marroquín Medical School, Guatemala City, Guatemala; Shripad Banavali, Tata Memorial Hospital, Mumbai, India; Luis Castillo, Hospital Pereira Rossell, Montevideo, Uruguay; Trijn Israels, Vrije Universiteit Medical Center, Amsterdam, the Netherlands; Sima Jeha and Ching-Hon Pui, St Jude Children's Research Hospital, Memphis, TN; Mhammed Harif, Centre Hospitalier Universitaire Mohammed VI, Marrakech, Morocco; Michael J. Sullivan, Royal Children's Hospital, Melbourne, Australia; Thuan Chong Quah, National University Health System, Singapore; Catherine Patte, Institute Gustave-Roussy, Villejuif, France; Ronald Barr, McMaster University and McMaster Children's Hospital, Hamilton, ON, Canada; and Thomas Gross, National Cancer Institute Center for Global Health, Bethesda, MD
| | - Ching-Hon Pui
- Carlos Rodriguez-Galindo and Paola Friedrich, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Patricia Alcasabas, Philippines General Hospital, Manila, Philippines; Federico Antillon, Unidad Nacional de Oncología Pediátrica, and Francisco Marroquín Medical School, Guatemala City, Guatemala; Shripad Banavali, Tata Memorial Hospital, Mumbai, India; Luis Castillo, Hospital Pereira Rossell, Montevideo, Uruguay; Trijn Israels, Vrije Universiteit Medical Center, Amsterdam, the Netherlands; Sima Jeha and Ching-Hon Pui, St Jude Children's Research Hospital, Memphis, TN; Mhammed Harif, Centre Hospitalier Universitaire Mohammed VI, Marrakech, Morocco; Michael J. Sullivan, Royal Children's Hospital, Melbourne, Australia; Thuan Chong Quah, National University Health System, Singapore; Catherine Patte, Institute Gustave-Roussy, Villejuif, France; Ronald Barr, McMaster University and McMaster Children's Hospital, Hamilton, ON, Canada; and Thomas Gross, National Cancer Institute Center for Global Health, Bethesda, MD
| | - Ronald Barr
- Carlos Rodriguez-Galindo and Paola Friedrich, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Patricia Alcasabas, Philippines General Hospital, Manila, Philippines; Federico Antillon, Unidad Nacional de Oncología Pediátrica, and Francisco Marroquín Medical School, Guatemala City, Guatemala; Shripad Banavali, Tata Memorial Hospital, Mumbai, India; Luis Castillo, Hospital Pereira Rossell, Montevideo, Uruguay; Trijn Israels, Vrije Universiteit Medical Center, Amsterdam, the Netherlands; Sima Jeha and Ching-Hon Pui, St Jude Children's Research Hospital, Memphis, TN; Mhammed Harif, Centre Hospitalier Universitaire Mohammed VI, Marrakech, Morocco; Michael J. Sullivan, Royal Children's Hospital, Melbourne, Australia; Thuan Chong Quah, National University Health System, Singapore; Catherine Patte, Institute Gustave-Roussy, Villejuif, France; Ronald Barr, McMaster University and McMaster Children's Hospital, Hamilton, ON, Canada; and Thomas Gross, National Cancer Institute Center for Global Health, Bethesda, MD
| | - Thomas Gross
- Carlos Rodriguez-Galindo and Paola Friedrich, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Patricia Alcasabas, Philippines General Hospital, Manila, Philippines; Federico Antillon, Unidad Nacional de Oncología Pediátrica, and Francisco Marroquín Medical School, Guatemala City, Guatemala; Shripad Banavali, Tata Memorial Hospital, Mumbai, India; Luis Castillo, Hospital Pereira Rossell, Montevideo, Uruguay; Trijn Israels, Vrije Universiteit Medical Center, Amsterdam, the Netherlands; Sima Jeha and Ching-Hon Pui, St Jude Children's Research Hospital, Memphis, TN; Mhammed Harif, Centre Hospitalier Universitaire Mohammed VI, Marrakech, Morocco; Michael J. Sullivan, Royal Children's Hospital, Melbourne, Australia; Thuan Chong Quah, National University Health System, Singapore; Catherine Patte, Institute Gustave-Roussy, Villejuif, France; Ronald Barr, McMaster University and McMaster Children's Hospital, Hamilton, ON, Canada; and Thomas Gross, National Cancer Institute Center for Global Health, Bethesda, MD
| |
Collapse
|
18
|
Taylor VM, Ko LK, Hwang JH, Sin MK, Inadomi JM. Gastric Cancer in Asian American Populations: a Neglected Health Disparity. Asian Pac J Cancer Prev 2015; 15:10565-71. [DOI: 10.7314/apjcp.2014.15.24.10565] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
19
|
Bae JM. Two hypotheses of dense breasts and viral infection for explaining incidence of breast cancer by age group in Korean women. Epidemiol Health 2014; 36:e2014020. [PMID: 25266421 PMCID: PMC4220604 DOI: 10.4178/epih/e2014020] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2014] [Accepted: 09/26/2014] [Indexed: 01/02/2023] Open
Abstract
Breast cancer, the second leading type of cancer in Korean women, has shown increasing incidence over the past 10 years. However, the curves of incidence by age group cast doubt on the birth cohort effect hypothesis. To explain the curves, here I suggest two alternative hypotheses of breast density and viral infection based on pre-existing evidences. Evaluating these hypotheses would require important clues to find unknown risk factors of breast cancer and to plan more effective strategies for breast cancer control in Korean women.
Collapse
Affiliation(s)
- Jong-Myon Bae
- Department of Preventive Medicine, Jeju National University School of Medicine, Jeju, Korea
| |
Collapse
|